This study is designed to find out if adding raltegravir reduces the amount of HIV in the blood using a test that measures very low amounts of the virus.

Inclusion Criteria:

• Men and women with documented HIV infection
• A viral load of more than 100,000 prior to starting HIV medicines
• On HIV medicines for more than 12 months
• No change in HIV medicines for 3 months
• HIV viral load less than 50 for at least 6 months on HIV medicines
• CD4 count above 200

Exclusion criteria:

• Currently pregnant or breastfeeding
• Unsuccessful control of HIV on a previous drug combination
• Unstable medical condition such as heart disease or cancer requiring ongoing therapy
• An opportunistic infection or other serious illness within 60 days prior to entry
• Plans to change your current HIV medicines within 24 weeks after study entry

This study is being conducted by Dr. Judith Currier under IRB #07-08-032-01

If you think you might be interested in participating in this study, please contact Deon Claiborne at 310-557-9062 or email at dclaiborne@mednet.ucla.edu

Return to Clinical Trials main page